Literature DB >> 31023087

Recent advances in the management of perianal fistulizing Crohn's disease: lessons for the clinic.

Nicole Lopez1, Sonia Ramamoorthy1, Willam J Sandborn2,3.   

Abstract

INTRODUCTION: Managing fistulizing perianal disease is among the most challenging aspects of treating patients with Crohn's disease. Perianal fistulas are indicative of poor long-term prognosis. They are commonly associated with significant morbidities and can have detrimental effects on quality of life. While durable fistula closure is ideal, it is uncommon. In optimal circumstances, reported long-term fistula healing rates are only slightly higher than 50% and recurrence is common. Achieving these results requires a combined medical and surgical approach, highlighting the importance of a highly skilled and collaborative multidisciplinary team. In recent years, advances in imaging, biologic therapies and surgical techniques have lent to growing enthusiasm amongst treatment teams, however the most advantageous approach is yet to be determined. Areas covered: Here we review current management approaches, incorporating recent guidelines and novel therapies. Additionally, we discuss recently published and ongoing studies that will likely impact practice in the coming years. Expert opinion: Investing in concerted collaborative multi-institutional efforts will be necessary to better define optimal timing and dosing of medical therapy, as well as to identify ideal timing and approach of surgical interventions. Standardizing outcome measures can facilitate these efforts. Clearly, experienced multidisciplinary teams will be paramount in this process.

Entities:  

Keywords:  Anorectal fistula; Crohn’s disease; anti-TNF; mesenchymal stem cells; perianal fistula; seton

Mesh:

Substances:

Year:  2019        PMID: 31023087      PMCID: PMC6545251          DOI: 10.1080/17474124.2019.1608818

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  88 in total

1.  The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota.

Authors:  David A Schwartz; Edward V Loftus; William J Tremaine; Remo Panaccione; W Scott Harmsen; Alan R Zinsmeister; William J Sandborn
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

2.  Infliximab for the treatment of fistulas in patients with Crohn's disease.

Authors:  D H Present; P Rutgeerts; S Targan; S B Hanauer; L Mayer; R A van Hogezand; D K Podolsky; B E Sands; T Braakman; K L DeWoody; T F Schaible; S J van Deventer
Journal:  N Engl J Med       Date:  1999-05-06       Impact factor: 91.245

3.  The clinical course of fistulating Crohn's disease.

Authors:  S J Bell; A B Williams; P Wiesel; K Wilkinson; R C G Cohen; M A Kamm
Journal:  Aliment Pharmacol Ther       Date:  2003-05-01       Impact factor: 8.171

Review 4.  AGA technical review on perianal Crohn's disease.

Authors:  William J Sandborn; Victor W Fazio; Brian G Feagan; Stephen B Hanauer
Journal:  Gastroenterology       Date:  2003-11       Impact factor: 22.682

5.  A randomized, controlled trial of fibrin glue vs. conventional treatment for anal fistula.

Authors:  Ian Lindsey; M M Smilgin-Humphreys; Chris Cunningham; Neil J M Mortensen; Bruce D George
Journal:  Dis Colon Rectum       Date:  2002-12       Impact factor: 4.585

6.  Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience.

Authors:  Dawnelle R Topstad; Remo Panaccione; John A Heine; Douglas R E Johnson; Anthony R MacLean; W Donald Buie
Journal:  Dis Colon Rectum       Date:  2003-05       Impact factor: 4.585

7.  Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease.

Authors:  C Dejaco; M Harrer; T Waldhoer; W Miehsler; H Vogelsang; W Reinisch
Journal:  Aliment Pharmacol Ther       Date:  2003-12       Impact factor: 8.171

8.  Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial.

Authors:  William J Sandborn; Daniel H Present; Kim L Isaacs; Douglas C Wolf; Eugene Greenberg; Stephen B Hanauer; Brian G Feagan; Lloyd Mayer; Therese Johnson; Joseph Galanko; Christopher Martin; Robert S Sandler
Journal:  Gastroenterology       Date:  2003-08       Impact factor: 22.682

9.  Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement.

Authors:  Miguel Regueiro; Houssam Mardini
Journal:  Inflamm Bowel Dis       Date:  2003-03       Impact factor: 5.325

10.  Infliximab maintenance therapy for fistulizing Crohn's disease.

Authors:  Bruce E Sands; Frank H Anderson; Charles N Bernstein; William Y Chey; Brian G Feagan; Richard N Fedorak; Michael A Kamm; Joshua R Korzenik; Bret A Lashner; Jane E Onken; Daniel Rachmilewitz; Paul Rutgeerts; Gary Wild; Douglas C Wolf; Paul A Marsters; Suzanne B Travers; Marion A Blank; Sander J van Deventer
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

View more
  11 in total

Review 1.  Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview.

Authors:  Amosy Ephreim M'Koma
Journal:  Medicina (Kaunas)       Date:  2022-04-21       Impact factor: 2.948

Review 2.  The Optimal Management of Fistulizing Crohn's Disease: Evidence beyond Randomized Clinical Trials.

Authors:  Panu Wetwittayakhlang; Alex Al Khoury; Gustavo Drügg Hahn; Peter Laszlo Lakatos
Journal:  J Clin Med       Date:  2022-05-28       Impact factor: 4.964

Review 3.  The Essential Role of a Multidisciplinary Approach in Inflammatory Bowel Diseases: Combined Medical-Surgical Treatment in Complex Perianal Fistulas in CD.

Authors:  Jeroen Geldof; Nusrat Iqbal; Janindra Warusavitarne; Ailsa Hart
Journal:  Clin Colon Rectal Surg       Date:  2022-01-17

4.  Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis.

Authors:  Konstantinos Papamichael; Niels Vande Casteele; Jenny Jeyarajah; Vipul Jairath; Mark T Osterman; Adam S Cheifetz
Journal:  Am J Gastroenterol       Date:  2021-05-01       Impact factor: 12.045

5.  Vedolizumab for perianal fistulizing Crohn's disease: systematic review and meta-analysis.

Authors:  Fares Ayoub; Matthew Odenwald; Dejan Micic; Sushila R Dalal; Joel Pekow; Russell D Cohen; David T Rubin; Atsushi Sakuraba
Journal:  Intest Res       Date:  2022-02-08

6.  Perianal fistulodesis - A pilot study of a novel minimally invasive surgical and medical approach for closure of perianal fistulae.

Authors:  Roxanne Villiger; Daniela Cabalzar-Wondberg; Daniela Zeller; Pascal Frei; Luc Biedermann; Christian Schneider; Michael Scharl; Gerhard Rogler; Matthias Turina; Andreas Rickenbacher; Benjamin Misselwitz
Journal:  World J Gastrointest Surg       Date:  2021-02-27

7.  Efficacy of stem cells therapy for Crohn's fistula: a meta-analysis and systematic review.

Authors:  Yantian Cao; Qi Su; Bangjie Zhang; Fangfang Shen; Shaoshan Li
Journal:  Stem Cell Res Ther       Date:  2021-01-07       Impact factor: 6.832

Review 8.  Unmet needs in inflammatory bowel disease.

Authors:  Joana Revés; Ryan C Ungaro; Joana Torres
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-11-30

9.  Follow-up Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel (Mesenchymal Stem Cell Treatment) in Patients With Perianal Fistulizing Crohn's Disease: ADMIRE-CD Phase 3 Randomized Controlled Trial.

Authors:  Damián Garcia-Olmo; Inmaculada Gilaberte; Matthias Binek; André J L D Hoore; Dirk Lindner; Francesco Selvaggi; Antonino Spinelli; Julian Panés
Journal:  Dis Colon Rectum       Date:  2022-05-01       Impact factor: 4.585

Review 10.  Managing complex perianal disease after anti-TNF failure: Where to go next?

Authors:  Clare Yzet; Franck Brazier; Charles Sabbagh; Mathurin Fumery
Journal:  Curr Res Pharmacol Drug Discov       Date:  2022-01-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.